Vigil Neuroscience, Inc. (NASDAQ:VIGL) Shares Sold by Point72 Asset Management L.P.

Point72 Asset Management L.P. cut its holdings in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 84.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 250,000 shares of the company's stock after selling 1,350,000 shares during the quarter. Point72 Asset Management L.P. owned 0.61% of Vigil Neuroscience worth $425,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of VIGL. Cubist Systematic Strategies LLC increased its holdings in shares of Vigil Neuroscience by 53.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after purchasing an additional 8,358 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Vigil Neuroscience during the 4th quarter valued at approximately $83,000. Barclays PLC increased its holdings in shares of Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after purchasing an additional 19,436 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Vigil Neuroscience by 29.0% during the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after purchasing an additional 14,572 shares in the last quarter. Finally, Boothbay Fund Management LLC purchased a new position in shares of Vigil Neuroscience during the 4th quarter valued at approximately $249,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on VIGL. Mizuho lowered shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Friday. Jefferies Financial Group lowered shares of Vigil Neuroscience to a "hold" rating in a report on Thursday, May 22nd. William Blair lowered shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 22nd. Guggenheim set a $8.00 price target on shares of Vigil Neuroscience and gave the stock a "neutral" rating in a report on Thursday, May 22nd. Finally, JMP Securities reissued a "market perform" rating on shares of Vigil Neuroscience in a report on Thursday, May 22nd. Nine investment analysts have rated the stock with a hold rating, According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $11.50.

Vigil Neuroscience Stock Performance

Shares of VIGL stock traded down $0.01 on Tuesday, hitting $7.88. 2,108,758 shares of the stock traded hands, compared to its average volume of 642,723. The firm's 50-day moving average price is $2.31 and its two-hundred day moving average price is $2.31. The stock has a market capitalization of $367.78 million, a PE ratio of -3.83 and a beta of 1.90. Vigil Neuroscience, Inc. has a twelve month low of $1.31 and a twelve month high of $7.95.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.04. On average, equities research analysts anticipate that Vigil Neuroscience, Inc. will post -2.07 EPS for the current fiscal year.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.